

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/014585 A1

(51) International Patent Classification⁷: C07D 405/04, 405/06, 405/14, 413/14, 417/14, A61K 31/395

(21) International Application Number:
PCT/CA2004/001466

(22) International Filing Date: 6 August 2004 (06.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/493,336 8 August 2003 (08.08.2003): US

(71) Applicant (for all designated States except US):
ULYSSES PHARMACEUTICAL PRODUCTS INC.
[CA/CA]; 238 Ch. d'Orford-sur-le Lac, Eastman, Quebec
J0E 1P0 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHAMBERLAND,
Suzanne [CA/CA]; 238 Ch. d'Orford-sur-le-Lac, Eastman,
Quebec J0E 1P0 (CA). MALOUIN, Francois [CA/CA];
238 Ch. d'Orford-sur-le-Lac, Eastman, Quebec J0E 1P0
(CA).

(74) Agents: SCHWARTZ, David, E. et al.; Smart & Biggar,
Suite 3300, 1000 de La Gauchetiere Street West, Montreal,
Quebec H3B 4W5 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report

(48) Date of publication of this corrected version:
9 September 2005

(15) Information about Correction:
see PCT Gazette No. 36/2005 of 9 September 2005, Sec-
tion II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS



(I)

(57) Abstract: The present invention includes novel com-
pounds of the formula (I) wherein X is absent or trans or
cis CHCH, R₁ is (C₁-C₁₀) alkyl unsubstituted or substituted
by one to three hydroxy, (C₁-C₁₀) alkenyl unsubstituted or
substituted by one to three hydroxy, (C₁-C₁₀) alkynyl un-
substituted or substituted by one to three hydroxy, or aryl
unsubstituted or substituted by one to three hydroxy; R₂ is
hydrogen, alkyl or aryl; R₃ and R₄ are, independently of
each other, H, halogen, or a solubilizing group, with the

proviso that at least one of R₃ and R₄ is halogen; and pharmaceutically acceptable salts thereof. The invention also includes pharma-
ceutically acceptable formulations of said compounds which exhibit antibiotic activity against a wide spectrum of microorganisms
including organisms which are resistant to multiple antibiotic families and are useful as antibacterial agents for treatment or prophy-
laxis of bacterial infections, or their use as antiseptics, agents for sterilization or disinfection.

WO 2005/014585 A1